Pitcairn’s Altimmune ALT Stock Holding History

Pitcairn’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,960	Closed	-$42.2K	–	642
2023 Q2	$42.2K	Sell	11,960 -4,301	-26%	-$19.3K	﹤0.01%	650
2023 Q1	$68.6K	Buy	+16,261	New	+$193K	0.01%	596

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pitcairn's ALT Position: Q3 2023 in Review

Pitcairn sold out of Altimmune (ALT) in Q3 2023, closing a stake of 11,960 shares — an estimated $42.2K sold.

Pitcairn first reported a position in ALT in Q1 2023 and held it in 2 quarters. The position peaked at $68.6K in Q1 2023. 112 funds tracked by Wall St. Rank hold ALT as of Q3 2023.

Pitcairn reported no remaining Altimmune position as of Q3 2023 after selling out during the quarter.
Pitcairn sold 11,960 Altimmune shares in Q3 2023, an estimated $42.2K.
Pitcairn first reported a position in Altimmune in Q1 2023 and held it in 2 quarters.
Pitcairn's Altimmune position peaked at $68.6K in Q1 2023.
112 funds tracked by Wall St. Rank held Altimmune as of Q3 2023.

Based on Pitcairn's 13F filing for Q3 2023, filed 13 Nov 2023.